
· Executive Brief
International Overdose Awareness Day 2026
An executive-guidance framework for access, qualified response, handoffs, escalation, and learning.

Leadership signal
International Overdose Awareness Day can serve as an executive operating checkpoint.
Awareness activity should not create an unsupported promise of service. Leaders can align public communication with actual entry points, qualified response capacity, emergency procedures, transition ownership, and a clear method for escalating unresolved needs.
Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.
Executive opening
Overdose prevention is a continuity problem as much as a supply problem
Overdose deaths are often discussed as a community crisis, but many of the moments that matter happen inside health systems. People at risk pass through emergency departments, psychiatric units, primary care clinics and discharge lounges. Each visit is a chance to hand someone naloxone, start treatment or connect them to a person who will follow up. Each missed chance is an operational failure, not only a clinical one. Leaders who map these moments can assign owners to them.
The national picture has shifted. One evaluation noted a national decline of more than 25% in opioid overdose deaths in 2024, while overdose remained a leading cause of mortality with persistent regional disparities.[6] Total U.S. naloxone distribution rose from 7.65 million units in 2018 to 29.7 million units in 2023.[1] Supply has grown quickly, yet the question for leaders is whether it reaches the right people at the right moment.
Continuity of treatment may matter as much as supply. In a community-level study of 67 communities with 8.2 million adults, increases in people treated with buprenorphine and people retained for more than 180 days were each associated with lower quarterly overdose death rates.[2] Retention, in other words, is a measure that executives can own. It depends on scheduling, prescribing access, insurance navigation and follow-up calls, all of which sit inside health-system operations.
This brief adds research evidence to the executive guidance already on this page. It covers naloxone distribution, emergency department treatment starts, peer recovery support, transitions after discharge and release, equity and public communication. It describes health-system operations and measures, not individual treatment decisions. The goal is to help leaders find the handoffs where people at risk are most often lost, and to decide which of those handoffs to fix first.
Current evidence
What current research says about burden, supply and retention
Naloxone supply has moved outside traditional health care settings. Sales to health care settings doubled from 6.3 million units in 2018 to 13.6 million units in 2023.[1] Over the same period, naloxone distributed to non-health care settings rose from an estimated 1.39 million units to 16.1 million units.[1] By 2023, that community channel accounted for 54% of all naloxone distributed in the United States.[1] The largest increase was in nasal spray devices, which rose from 2.9 million to 23.4 million.[1] Health systems are now one channel among many, which makes coordination with community distributors part of the job.
Community supply alone does not guarantee lower mortality. In the HEALing Communities Study data, the 2019 annual rates were 40.4 opioid overdose deaths and 1,287 naloxone rescue units distributed per 100,000 population.[2] An increase of 100 people treated with buprenorphine per 100,000 population was associated with a decrease of 0.92 in the quarterly opioid overdose death rate.[2] An increase of 100 people retained for more than 180 days was associated with a decrease of 1.3.[2] The study found no statistically significant association between naloxone distribution and change in quarterly death rates.[2]
That finding does not argue against naloxone. It argues for measuring both rescue and retention, because they serve different purposes. A statewide program in Illinois found a statistically significant relationship between naloxone orders and administrations, suggesting that more community availability was associated with more overdose reversals.[6] Illinois had reported nearly 4,000 overdose deaths in 2022.[6]
Hospital data show who reaches inpatient care after an overdose. Among 479,175 hospitalizations for opioid overdose in a national inpatient sample, males accounted for 52% and had higher mortality than females, with an adjusted odds ratio of 1.13.[13] White patients had the highest mortality, while Black patients were more likely to need noninvasive ventilation and hemodialysis.[13]
Risk also concentrates at transitions. Among 33,811 people released from Washington State prisons, drug overdose was the leading cause of death at 216 per 100,000 person-years.[15] The greatest substance-related mortality risk occurred within two weeks after release.[15] Psychostimulant-related mortality, at 152 per 100,000 person-years, exceeded opioid-related mortality at 138 per 100,000 person-years in that cohort.[15] For health systems, that two-week window is a planning target, not an abstraction, and overdose prevention cannot focus on opioids alone.
Figure 1
Naloxone and treatment handoffs reach only part of the people at risk
Percent of patients, recipients or units reaching each step, as reported in each study. Values are copied from the cited studies [1], [8], [9], [10]; none is estimated.
Data note. These values come from different studies, settings and denominators, so this is an indirect comparison; only the two bars from the same pilot can be read side by side.
Limitation. Most values come from single programs or hospitals; the national value is an estimate from distribution data.
Figure data (5 rows)
| Measure | Value | Population, setting and year as reported | Source |
|---|---|---|---|
| Outpatient follow-up within 30 days after ED observation unit buprenorphine start | 24% | Overall cohort of 55 patients, one large urban hospital, July 2023 to June 2024 | [10] |
| At-risk psychiatric inpatients given a naloxone kit before discharge | 37.8% | 90 patients at elevated overdose risk, 64-bed psychiatric hospital, December 2023 to March 2024 | [8] |
| Buprenorphine prescriptions renewed after street medicine initiation | 44% | 115 people experiencing homelessness started on buprenorphine in 2023, single program | [9] |
| Share of U.S. naloxone distributed to non-health care settings | 54% | Estimated from manufacturer and sales data, United States, 2023 | [1] |
| Treatment success in ED observation unit buprenorphine pathway | 60% | 33 of 55 patients, same pilot | [10] |

Continuum of care
Where the overdose continuum breaks between settings
The overdose continuum runs from community rescue to emergency care, treatment start, follow-up and long-term retention. Breaks can occur at every step. A quality improvement review at a 64-bed psychiatric hospital found that only 37.8% of patients identified as being at elevated risk for opioid overdose received a naloxone kit before discharge.[8] Although every surveyed resident felt responsible for offering kits, approximately one third rarely did so, citing time constraints and workflow confusion.[8]
Emergency departments are a frequent point of contact, but follow-up remains fragile. In a pilot at a large urban hospital, 55 patients were enrolled in an observation unit pathway for rapid low-dose buprenorphine initiation.[10] Thirty-three of them, or 60%, achieved treatment success, exceeding the prespecified feasibility threshold.[10] Yet only 24% of the overall cohort attended outpatient follow-up within 30 days, and opioid-related emergency department return within 90 days occurred in 40% overall.[10]
Clinicians see the same weak link, and they describe it in operational terms. In a survey at a single academic emergency department serving a rural population, inability to ensure follow-up was a primary barrier to buprenorphine initiation.[14] Clinicians named pharmacists, referral resources, peer recovery support specialists and care managers as primary facilitators.[14] Those are system resources, not individual skills. X-waivered clinicians felt more prepared, yet they were not more likely to report ordering buprenorphine or naloxone in the prior three months.[14] Preparation without a working referral route did not translate into more treatment starts.
Treatment can also begin outside clinic walls. A street medicine program started buprenorphine for 115 people experiencing homelessness in 2023.[9] Opioid use disorder-related emergency department visits fell from 79 in the 12 months before initiation to 44 in the 12 months after.[9] Only 44% of patients renewed their prescriptions, 13% through street medicine and 31% through another provider.[9] Overdose-related emergency department visits decreased non-significantly from 26 to 13.[9] Renewal through other providers shows how often continuity depends on a handoff that no single team controls.
Release from prison is a distinct transition. The Washington State cohort recorded 862 deaths among people released from prison and an all-cause mortality rate of 747 per 100,000 person-years.[15] The authors noted that continued surveillance of post-release mortality may improve overdose interventions.[15] Older age at most recent release, previous incarceration and drug-related convictions were significant risk factors for all-cause and overdose mortality.[15] Health systems that partner with correctional health services can plan for the first days after release. That planning includes medication continuity, a booked appointment, naloxone in hand and a contact who knows the person is coming.
Figure 3
Why the pathway breaks
People
- Clinicians feel responsible but rarely offer naloxone
- Experienced clinicians less likely to see buprenorphine as in scope
- Peer roles without clear outcome expectations
Process
- Naloxone at discharge not offered by default
- No owner for follow-up after an emergency department treatment start
- No plan for the first two weeks after release
Technology
- Distribution data not mapped against overdose burden
- Follow-up and renewal not tracked across providers
- Demographic data on recipients incomplete
Environment
- Rural residents traveling farther for naloxone
- Homelessness disrupting continuity
- Regions with low distribution despite similar burden
Policy
- Cost and ordering barriers for partner organizations
- Stigma limiting participation
- Uneven correctional and community partnerships
Measurement
- Treatment starts counted but retention not
- Outcomes not stratified by race, sex or rurality
- Peer program results judged only on utilization
Unranked qualitative cause-and-effect diagram for the outcome in the box: People at risk of overdose leave a health-system encounter without naloxone, a treatment start or a confirmed next contact Causes are assembled from the cited literature [3], [4], [6], [8], [9], [10], [12], [14], [15]; categories are not weighted and their order carries no meaning.
Data note. Qualitative; no frequencies are implied.
Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.
Figure data (6 rows)
| Category | Causes drawn from the cited literature |
|---|---|
| People | Clinicians feel responsible but rarely offer naloxone; Experienced clinicians less likely to see buprenorphine as in scope; Peer roles without clear outcome expectations |
| Process | Naloxone at discharge not offered by default; No owner for follow-up after an emergency department treatment start; No plan for the first two weeks after release |
| Technology | Distribution data not mapped against overdose burden; Follow-up and renewal not tracked across providers; Demographic data on recipients incomplete |
| Environment | Rural residents traveling farther for naloxone; Homelessness disrupting continuity; Regions with low distribution despite similar burden |
| Policy | Cost and ordering barriers for partner organizations; Stigma limiting participation; Uneven correctional and community partnerships |
| Measurement | Treatment starts counted but retention not; Outcomes not stratified by race, sex or rurality; Peer program results judged only on utilization |
Access
Putting naloxone and treatment within reach
Access starts with how naloxone reaches people. In Rhode Island in 2024, 91.3% of people who received naloxone from community agencies got it in person, and 51.8% of interactions came through mobile outreach.[4] Most recipients, 91.3%, received naloxone within 10 miles of their residence ZIP code.[4] People living in rural areas, women and gender minorities, and people under 25 more commonly used mail delivery or traveled farther.[4]
Geography shapes access even within a small state. From 2022 to 2024, Rhode Island community agencies distributed 124,606 naloxone kits.[3] Distribution varied substantially across the state, even among regions with similar overdose burden.[3] Three of the state’s ten regions consistently had the lowest distribution across all four measures and were selected for interventions to increase it.[3] Regions with a higher burden of overdoses generally had higher distribution, but the variation showed that burden alone did not determine supply.[3] Health systems can use the same saturation approach to map their own discharge and pharmacy distribution.
Program design affects participation. In Illinois, a statewide program provided free nasal naloxone through an online portal to community organizations, hospitals and clinics.[6] Interviews with 15 policymakers, partners and participating organizations emphasized no-cost access and a simple ordering process.[6] Free and streamlined ordering were key facilitators, and naloxone use increasingly occurred in residential settings.[6]
Treatment access depends on where initiation can happen. The emergency department observation unit pilot offered a structured setting for patients not in sufficient withdrawal for standard induction.[10] The street medicine program brought buprenorphine to people experiencing homelessness.[9] Both models extend access to people who may not reach a traditional clinic or who have had poor experiences in one. Both also need a defined route into ongoing care once the first prescription runs out.
Access must also survive the hours after a rescue. The Illinois evaluation reported a decline in 911 calls and hospitalizations after naloxone administration as use shifted toward residential settings.[6] That shift may mean fewer people reach the emergency department after an overdose. Health systems may need outreach, telehealth and community partner referrals to offer treatment to people who are revived at home and never arrive at a hospital.
Executive guidance · System route
Build one visible operating route for International Overdose Awareness Day.
Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.
The route at a glance
- Make access clear
- Protect privacy
- Protect respectful continuity
- Hold the transition
- Learn without stigma
Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.
Make access clear
Use respectful, plain-language instructions that identify approved contact options and what a person can expect next.
Protect privacy
Review channels, spaces, documentation, and role access against organizational policy and applicable requirements.
Protect respectful continuity
Align clear access, privacy, qualified response, approved escalation, and transition ownership without making assumptions about any person.
Hold the transition
Confirm acceptance when responsibility moves, and use approved escalation when the next owner is unavailable.
Learn without stigma
Review delays, drop-offs, repeat contacts, and experience feedback to improve the system rather than judge the person.
Figure 2
The system route as one flow
The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.
Data note. Shows sequence and handoffs only; it carries no counts or rates.
Limitation. Local processes may add, merge or reorder stages under organizational policy.
Figure data (5 rows)
| Stage | What the stage requires |
|---|---|
| Make access clear | Use respectful, plain-language instructions that identify approved contact options and what a person can expect next. |
| Protect privacy | Review channels, spaces, documentation, and role access against organizational policy and applicable requirements. |
| Protect respectful continuity | Align clear access, privacy, qualified response, approved escalation, and transition ownership without making assumptions about any person. |
| Hold the transition | Confirm acceptance when responsibility moves, and use approved escalation when the next owner is unavailable. |
| Learn without stigma | Review delays, drop-offs, repeat contacts, and experience feedback to improve the system rather than judge the person. |
Equity and trust
Who receives naloxone and who is left out
Distribution totals can hide uneven reach. A survey of 241 no-cost naloxone distributors in North Carolina found that at least one distributor served all demographic populations in over 92% of ZIP codes.[5] Yet the non-Hispanic White group had the highest mean naloxone distribution score, 30.2.[5] After adjusting for population size, all minority race and ethnicity groups had significantly lower distribution than the non-Hispanic White group.[5]
Outcomes after overdose also differ by group. In national inpatient data, Black patients hospitalized for opioid overdose had stable mortality over time but were more likely to need noninvasive ventilation, with an adjusted odds ratio of 1.27.[13] They were also more likely to need hemodialysis, with an adjusted odds ratio of 1.28.[13] Mortality declined over time for both sexes, with females showing greater reductions in severe outcomes such as cardiac arrest.[13] These patterns call for stratified quality reporting, not a single average.
Equity gaps can also emerge in who benefits from a program. The Illinois evaluation found a rise in naloxone administrations among Black individuals and a decline among Hispanic populations.[6] The authors pointed to disparities in naloxone administration responses and institutional participation and called for continued efforts to reduce stigma.[6] Health systems that distribute naloxone can review their own data by race, ethnicity, language and neighborhood. Where gaps appear, community organizations trusted by those groups are often better placed to close them than a hospital acting alone.
Trust shapes whether people accept help. Among 614 college students surveyed at one university, 84.5% supported naloxone distribution on campus, and lower stigma toward people who use drugs was significantly associated with support.[7] In the same survey, 17.1% had witnessed an overdose and 44.2% knew someone who had died of a fatal drug overdose.[7] Students in interviews said they wanted low-barrier or no-barrier access to naloxone.[7]
In Rhode Island, mail delivery and longer-distance distribution reached rural residents, women, gender minorities and younger people more often.[4] Offering several routes, rather than one, appears to reach a more diverse population.[4] For executives, equity means designing several doors and checking who uses each. It also means asking communities which doors feel safe, since a route that exists on paper may not be one people trust.

Human infrastructure
The people who carry the overdose handoff
Peer recovery support specialists have become a common part of emergency department overdose responses. A systematic review of comparative studies screened 1,093 records and included nine studies representing 14,883 individuals.[11] The findings were mixed, and peer support had not yet demonstrated clear superiority over non-peer comparators.[11] The authors noted that quantitative studies may miss the patient experience of working with a peer.[11]
A Nevada evaluation shows why expectations should be set carefully. Certified peer recovery support specialists delivered an emergency department intervention in 3 hospitals, and 4,643 patients were analyzed, including 631 who received the intervention.[12] The study did not observe a clinically significant effect on emergency department or inpatient utilization.[12] The authors called for more attention to multiple substances and patient-centered outcomes.[12]
Those results do not mean peers lack value. They mean leaders should define what peers are expected to change, such as treatment linkage, engagement or patient experience, and measure those outcomes directly. Peer roles also need supervision, career paths and protection from burnout. Without that support, programs may struggle to retain the people whose lived experience makes them effective.
Clinical teams need preparation too. In the academic emergency department survey, 83% of clinicians said they would be interested in additional education about opioid use disorder treatment.[14] Agreement that buprenorphine prescribing falls within emergency clinicians’ scope of practice was inversely correlated with average years in practice.[14] Training that reaches experienced clinicians may therefore matter as much as training for new staff.
Workflow design is a workforce issue. On the inpatient psychiatric units, residents cited time constraints and workflow confusion as reasons for not offering naloxone.[8] The authors recommended offering naloxone to all patients at discharge and streamlining workflow procedures.[8] Default processes reduce the load on individual clinicians.
The emergency department review noted that opioids were the most commonly evaluated substance, studied in seven of the nine included studies, and overdose was evaluated in six.[11] Most of the included studies were rated moderate for global risk of bias.[11] Matching peer program goals to the outcomes where evidence is strongest is a practical way to plan staffing and evaluation.
Executive guidance · Operating dashboard
Use a small dashboard to expose friction and ownership.
Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.
Four operating signals
Each signal pairs an executive question with one candidate local measure, set out below.
Executive guidance · Signal
Access clarity
Can people understand where to begin and what will happen after contact?
- Candidate local measure
- Locally defined contact, routing, response, and repeat-contact signals.
Executive guidance · Signal
Privacy reliability
Do channels, roles, and spaces support organizational privacy expectations?
- Candidate local measure
- Reported privacy barriers, process exceptions, training needs, and corrective-action status.
Executive guidance · Signal
Respectful continuity
Can people reach qualified support and remain connected through transitions without stigma or unowned work?
- Candidate local measure
- Locally defined access barriers, repeat contacts, unaccepted transfers, escalation, and experience feedback.
Executive guidance · Signal
Experience and learning
Can people and staff identify barriers without stigma or futility?
- Candidate local measure
- Feedback themes, assigned improvements, response status, and verified changes.
Figure 4
The operating system behind the dashboard
The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.
Data note. Structural diagram; no measured values.
Limitation. Owners are candidates to be confirmed locally.
Figure data (4 rows)
| Operating signal | Candidate owner |
|---|---|
| Access clarity | Executive sponsor and operational lead |
| Privacy reliability | Operational owner and participating teams |
| Respectful continuity | Sending and receiving owners |
| Experience and learning | Improvement owner and executive sponsor |
Executive guidance · Handoff workflow
Close the loop across teams, settings, and partners.
A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.
How responsibility moves
Lane A
From message to accepted ownership
- Confirm the approved message and intended audience.
- Publish the actual entry point and receiving role.
- Acknowledge receipt using the locally approved method.
- Escalate when ownership or response remains unclear.
Lane B
From accepted ownership to verified follow-through
- Record the next accountable owner and visible status.
- Use the approved private channel, name the qualified receiver, and preserve visibility under local escalation policy.
- Keep unresolved work visible across boundaries.
- Confirm closure or document the continuing exception.
Executive guidance · Executive scorecard
Give leaders one view of route reliability and improvement.
The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.
Who reviews what
- Executive sponsor and operational lead
- Operational owner and participating teams
- Sending and receiving owners
- Improvement owner and executive sponsor
Candidate owners named in the scorecard, confirmed locally.
| Operating signal | Executive question | Candidate owner | Suggested review point |
|---|---|---|---|
| Access clarity | Can people understand where to begin and what will happen after contact? | Executive sponsor and operational lead | At campaign launch and close |
| Privacy reliability | Do channels, roles, and spaces support organizational privacy expectations? | Operational owner and participating teams | At a locally defined cadence |
| Respectful continuity | Can people reach qualified support and remain connected through transitions without stigma or unowned work? | Sending and receiving owners | At a locally defined cadence |
| Experience and learning | Can people and staff identify barriers without stigma or futility? | Improvement owner and executive sponsor | Until action is verified |
Figure 5
Control points for overdose continuity
| Control point | Risk if missing | Owner | Evidence of control |
|---|---|---|---|
| Naloxone offered by default at discharge from high-risk units | At-risk patients leave without rescue medication | Chief nursing officer and pharmacy director | Share of at-risk discharges with naloxone dispensed or documented as declined |
| Named owner for follow-up after an emergency department buprenorphine start | Patients lose treatment when the first prescription ends | Emergency medicine chair with behavioral health service line | Share of patients with a confirmed outpatient visit within 30 days |
| Release and discharge planning for the first two weeks | Highest-risk window passes without contact | Population health leader with correctional and community partners | Documented next contact and naloxone at release or discharge |
| Distribution mapped against overdose burden | Supply concentrates where it is easiest to deliver | Community health and analytics leads | Kits per fatal and nonfatal overdose by region, reviewed quarterly |
| Stratified equity reporting | Gaps by race, sex, age and rurality stay hidden | Chief health equity officer | Dashboard showing distribution, treatment and retention by group |
| Peer program outcome definitions | Programs judged on outcomes they were not designed to change | Behavioral health director | Agreed linkage, engagement and experience measures with supervision plan |
| Retention measured alongside treatment starts | Starts rise while continuity falls | Chief quality officer | Patients retained beyond 180 days reported with starts |
Control points derived from the cited evidence [2], [3], [5], [8], [10], [11], [12], [13], [15] and this brief’s executive guidance.
Data note. Each row is a control to verify, not a measured result.
Limitation. Owners and evidence of control must follow local policy and applicable requirements.
Public communication
Talking about overdose without stigma or false comfort
Public communication on overdose has to balance progress with urgency. National data show a decline in deaths, yet overdose remains a leading cause of mortality with persistent regional disparities.[6] Messages that celebrate declines without naming gaps can weaken support for the services that produced them. Messages that only describe crisis can make prevention feel futile. The most credible message pairs a clear statement of risk with a specific action the listener can take.
Stigma is a communication problem and an access problem. In the college survey, positive perceptions about naloxone, familiarity with people who use drugs and lower stigma were all associated with support for distribution.[7] The Illinois evaluation likewise called for continued efforts to reduce stigma and promote harm reduction education.[6] Health-system messages can model respectful language that treats overdose as a preventable medical event. Clinicians, security staff and front-desk teams shape that message at every encounter, not only in campaigns.
Communication inside the system matters as much as public campaigns. Psychiatry residents on inpatient units described workflow confusion about offering naloxone.[8] Emergency clinicians cited lack of knowledge of available resources as a barrier to starting buprenorphine.[14] Clear internal guidance about who offers naloxone, who starts treatment and who books follow-up is the foundation for any external message.
Leaders can also report their own measures openly. The Rhode Island approach compared kits per fatal overdose, per nonfatal overdose and per 100,000 residents to find gaps.[3] Publishing similar local measures, including follow-up and retention by community, shows partners where the system is working and where help is needed. It also invites correction from the people closest to the problem, including people who use drugs, families and community distributors.
Finally, communication should reach people at the transitions where risk peaks. Overdose risk was highest within two weeks of release from prison in the Washington State cohort.[15] Discharge materials, release planning and community partner messages can name a specific next contact for that window. Messages should be short, practical and available in the languages people speak. They should also explain where to get naloxone without cost and what to expect at a first treatment visit, so the next step feels concrete.

Executive guidance · 90-day plan
Turn the observance into one sustained operating change.
The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.
Ninety days, three moves
- Days 1–30See the current route
- Days 31–60Build the reliable path
- Days 61–90Make the change visible
Days 1–30 · Listen and map
See the current route
- Name an executive sponsor and an operational owner.
- Listen to people using the route and representative frontline teams.
- Map how International Overdose Awareness Day communications connect to real entry points, owners, transitions, and escalation.
- Select one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and test
Build the reliable path
- Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
- Validate the design with every sending and receiving team involved.
- Test one respectful access-to-qualified-support handoff and remove a verified privacy, clarity, or ownership barrier.
- Test the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verify
Make the change visible
- Launch the redesigned route with a small set of locally defined measures.
- Review unresolved work and recurring friction using a learning approach.
- Correct implementation barriers and record who owns each remaining dependency.
- Report what changed, what evidence was reviewed, and what still requires live oversight.
Figure 6
The 90-day plan on one timeline
The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.
Data note. Time boxes are a management framework, not a clinical timeline.
Limitation. Durations are uniform 30-day windows; real tasks may span windows.
Figure data (12 rows)
| Window | Action |
|---|---|
| Days 1–30 · Listen and map | Name an executive sponsor and an operational owner. |
| Days 1–30 · Listen and map | Listen to people using the route and representative frontline teams. |
| Days 1–30 · Listen and map | Map how International Overdose Awareness Day communications connect to real entry points, owners, transitions, and escalation. |
| Days 1–30 · Listen and map | Select one recurring barrier that the organization can responsibly address. |
| Days 31–60 · Design and test | Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal. |
| Days 31–60 · Design and test | Validate the design with every sending and receiving team involved. |
| Days 31–60 · Design and test | Test one respectful access-to-qualified-support handoff and remove a verified privacy, clarity, or ownership barrier. |
| Days 31–60 · Design and test | Test the route in more than one representative setting or operating period where practical. |
| Days 61–90 · Implement and verify | Launch the redesigned route with a small set of locally defined measures. |
| Days 61–90 · Implement and verify | Review unresolved work and recurring friction using a learning approach. |
| Days 61–90 · Implement and verify | Correct implementation barriers and record who owns each remaining dependency. |
| Days 61–90 · Implement and verify | Report what changed, what evidence was reviewed, and what still requires live oversight. |
Executive guidance · Leadership close
Make International Overdose Awareness Day a starting point, not an endpoint.
Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.
Leadership commitment
Make ownership visible, test the route, and report what improved.
Executive action kit · Day observance
Turn International Overdose Awareness Day into accountable action.
An executive-guidance framework for access, qualified response, handoffs, escalation, and learning.
Leadership focus
Use this observance to examine psychological safety, timely connection, privacy, and continuity. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.
Workforce lens
Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the support, referral, privacy, escalation, and continuity pathway.
Patient and community lens
Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.
Equity and access lens
Review stigma, language, cultural safety, disability access, geography, cost, and digital barriers without assuming the same experience for every person.
Five-minute briefing
Inspect the operating sequence
Listen with people seeking support, behavioral health teams, emergency pathways, primary care, and community partners. Find one stigma, unclear ownership, a failed connection, or a privacy concern, then test the locally approved route from entry through acknowledged follow-through.
- Make access clear
- Protect privacy
- Protect respectful continuity
- Hold the transition
- Learn without stigma
Leadership actions for this week
- Name an executive sponsor and frontline operating owner.
- Ask people using and operating the pathway where ownership becomes unclear.
- Test one representative route from first question to acknowledged next step.
- Select one barrier that can be corrected without overstating the evidence.
- Set a review date and define how completion will be verified.
Candidate measures
Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.
- Locally defined contact, routing, response, and repeat-contact signals.
- Reported privacy barriers, process exceptions, training needs, and corrective-action status.
- Locally defined access barriers, repeat contacts, unaccepted transfers, escalation, and experience feedback.
Department readiness checklist
- The public and staff entry points match the actual approved process.
- A specific role accepts each request, referral, or escalation.
- Handoffs include acknowledgment and a visible unresolved state.
- Language, disability, digital, transportation, and trust barriers receive explicit review.
- Communications do not introduce unsupported themes, statistics, or clinical advice.
- A named leader will review what changed after the observance.
Intended audiences
- Executive and Operational Leaders
- Public Health and Community Partners
- Patient Experience and Access Leaders
Staff communication template
During International Overdose Awareness Day, our organization will connect awareness with a practical review of the support, referral, privacy, escalation, and continuity pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.
Community communication template
International Overdose Awareness Day is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.
Measurement worksheet
- Signal
- What observable condition will show whether the route works?
- Definition
- What is included, excluded, and counted?
- Owner
- Who reviews the signal and acts on exceptions?
- Cadence
- When will leaders review it?
- Equity check
- Which differences require protected, locally appropriate review?
- Closure
- What evidence will confirm the improvement was completed?
- Editorial review
- Completed
- Source records
- 2 listed under Authoritative resources
- Review standard
- Sourced facts remain separated from original executive guidance
- Clinical boundary
- No new statistical or clinical claim was added by this action kit
Sources and content boundary
Authoritative resources
Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.
Peer-reviewed references
References
Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .
- 1.Woods C, Chai G, Yoo JW, Dal Pan G. Naloxone Distribution in the United States, 2018-2023. American Journal of Public Health. 2026;116(10):1613-1616. https://doi.org/10.2105/ajph.2026.308541
- 2.Walley AY, Cheng DM, Vandergrift N, Larochelle M, Holloway J, Brown JL, et al. The association between naloxone distribution, buprenorphine treatment and retention and incident high-risk opioid prescribing with opioid overdose death in Kentucky, Massachusetts, New York and Ohio, United States: An exploratory community-level cohort study of data from the HEALing Communities Study. Addiction. 2026;121(9):2482-2493. https://doi.org/10.1111/add.70478
- 3.Shin J, Hallowell BD, Marshall BDL, Krieger MS, St John K. Using naloxone saturation measures and opioid overdose burden to optimize geographic distribution of naloxone in Rhode Island. Journal of Substance Use and Addiction Treatment. 2026;191:210091. https://doi.org/10.1016/j.josat.2026.210091
- 4.Ahern C, St John K, Koziol J, Jacobson A. Demographic Differences in Access to Community-Based Naloxone Distribution in Rhode Island, 2024. Journal of Public Health Management and Practice. 2026;32(6):912-918. https://doi.org/10.1097/phh.0000000000002397
- 5.Marley G, Shubel C, Annis IE, Delamater PL, Thorpe CT, Parikh B, et al. Evaluating demographic variation in no-cost naloxone distribution in North Carolina: a cross-sectional survey study. Harm Reduction Journal. 2026;23(1). https://doi.org/10.1186/s12954-026-01505-y
- 6.Beeler S, Golan O, Call A, Marino N, Ghobadi A, Monahan K. A mixed-methods evaluation of a statewide naloxone distribution project: considerations for future implementation of opioid overdose prevention initiatives. BMC Public Health. 2026;26(1). https://doi.org/10.1186/s12889-026-26921-4
- 7.Kirk MR, Wagner KD, Devereux PG, Larson MJ. “It’s a no-brainer to me.” A mixed methods analysis of students’ perceptions of naloxone distribution on their college campus. Journal of American College Health. 2026;74(2):537-546. https://doi.org/10.1080/07448481.2025.2538072
- 8.Stevens K, Urmanche A, Lynch ST. Naloxone Distribution on the Inpatient Psychiatric Unit: Identifying Gaps Between Current Prescribing Practices and Patient Need. Substance Use & Misuse. 2026;61(8):1304-1310. https://doi.org/10.1080/10826084.2025.2602836
- 9.Wallace CR, King J, Nichols T, Abrams EA, Shaw S, Hoeflinger NK, et al. Buprenorphine initiation by a street medicine program is associated with reduced opioid-related emergency department utilization among people experiencing homelessness. Drug and Alcohol Dependence. 2026;286. https://doi.org/10.1016/j.drugalcdep.2026.113258
- 10.Buckley C, Doukas D, Eloma-Ata A, Feuerbach A, Lavadera P, Berland NG, et al. Feasibility of rapid low dose buprenorphine initiation in an emergency department observation unit. American Journal of Emergency Medicine. 2026;100:79-86. https://doi.org/10.1016/j.ajem.2025.11.020
- 11.Chardavoyne PC, Bormann NL, Smartt AB, Nickels ZC, Gerberi D, Arndt S, et al. Emergency Department Peer Recovery Support Services for Individuals with Substance Use Disorders: A Systematic Review of Comparative Studies. Substance Abuse and Rehabilitation. 2026;17. https://doi.org/10.2147/sar.s609242
- 12.Wagner KD, Kirk MR, Lu M, Langhans J, Wei X, Woodard SA, et al. Evaluation of an Emergency Department-Based Peer Recovery Support Intervention for People Who Use Substances in Nevada. Substance Use & Addiction Journal. 2026;47(3):728-737. https://doi.org/10.1177/29767342251413972
- 13.Quazi MA, Goyal A, Khan T, Madi M, Faiz Z, Macias AGO, et al. Racial and sex disparities in inpatient outcomes of patients with opioid overdose: a nationwide analysis. Baylor University Medical Center Proceedings. 2025;38(6):859-871. https://doi.org/10.1080/08998280.2025.2546764
- 14.Barkley A, Lander L, Dilcher B, Tuscano M. Initiation of Buprenorphine in the Emergency Department: A Survey of Emergency Clinicians. Western Journal of Emergency Medicine. 2024;25(4):470-476. https://doi.org/10.5811/westjem.18029
- 15.O’Connor AW, Sears JM, Fulton-Kehoe D. Overdose and substance-related mortality after release from prison in Washington State: 2014–2019. Drug and Alcohol Dependence. 2022;241. https://doi.org/10.1016/j.drugalcdep.2022.109655
Claim-to-source matrix
What each source supports
Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.
| Claim group | Sources | Years | Used in | Limitation |
|---|---|---|---|---|
| National naloxone supply and community distribution channels | [1] | 2026 | Current evidence | Manufacturer and sales data estimate distribution, not use or reach to people at highest risk. |
| Community buprenorphine treatment, retention and overdose death rates | [2] | 2026 | Current evidence | Exploratory observational analysis at community level; associations, not individual effects. |
| Statewide no-cost naloxone program implementation | [6] | 2026 | Access | Program tracking data and 15 interviews from one state; administrations depend on reporting. |
| Geographic and demographic gaps in naloxone distribution | [3] [4] [5] | 2026 | Equity and trust | State-specific data with self-reported demographics or survey-based distribution scores. |
| Naloxone at inpatient psychiatric discharge | [8] | 2026 | Continuum of care | Single-hospital quality improvement chart review of 90 patients. |
| Emergency department and street medicine buprenorphine initiation | [9] [10] [14] | 2026, 2024 | Continuum of care | Single-center pilot, retrospective review and clinician survey; small samples and no randomized comparison. |
| Peer recovery support in emergency departments | [11] [12] | 2026 | Human infrastructure | Heterogeneous studies with moderate risk of bias; nonrandomized Nevada evaluation with group differences. |
| Inpatient outcomes after overdose by sex and race | [13] | 2025 | Equity and trust | Administrative national inpatient data rely on coding and capture only hospitalized patients. |
| Mortality after release from prison | [15] | 2022 | Current evidence | Single state cohort released 2014 to 2018; drug supply has changed since. |
| Stigma and support for campus naloxone distribution | [7] | 2026 | Public communication | Single-university survey and convenience-sample interviews. |

About the author
Greg Wahlstrom
MBAHCM
President and Chief Executive Officer, The Healthcare Executive
View Greg’s profile©2014 – 2026 The Healthcare Executive. All rights reserved.

